AOD-9604
A fragment of human growth hormone studied for fat loss without IGF-1 effects.
Back to all peptides
✨ real molecule sketch
Vendor listed this name?
AOD-9604
Research suppliers reuse acronyms and blend names—confirm identity before assuming you know the compound.
Pharmacokinetic snapshot
Reference values from published sources—not prescribing or dosing advice. Cosmetic INCI peptides do not belong here; injectable and prescription contexts only.
- Half-life
- ~30 min
- Typical dose range
- 250 mcg–1 mg
- Common frequency
- Often daily (unapproved)
Source: PubMed AOD-9604
Structure (cute edition)
✨ real molecule sketch
This peptide is a short chain of about 4 amino acids—think of it as a tiny protein necklace on your label.
INCI: AOD-9604 · ~4 amino acids in our simplified view
Research & public records
Counts and links from public databases (PubMed, ClinicalTrials.gov, Wikidata, NIH drug nomenclature). Educational only — not medical advice.
Knowledge base: chemical compound
PubMed: 11 indexed papers (search PubMed)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. · Sports medicine (Auckland, N.Z.)
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews
- Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. · Journal of separation science
- Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. · Expert review of proteomics
- Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls. · Journal of pharmaceutical and biomedical analysis
- AOD-9604 does not influence the WADA hGH isoform immunoassay. · Drug testing and analysis
- Obesity drugs in clinical development. · Current opinion in investigational drugs (London, England : 2000)
- Gateways to clinical trials. · Methods and findings in experimental and clinical pharmacology
Clinical trials: 5 studies on ClinicalTrials.gov (view search)
- Cardiovascular Risk Assessment in Patients With Severe Psoriasis Treated With Biologic Agents · COMPLETED
- Mechanistic Study of Anti-Platelet Therapy in Atherosclerosis · NOT_YET_RECRUITING
- Clinical Trial to Evaluate the Accuracy of [99mTc] ThromboView in the Detection of Deep Vein Thrombosis · COMPLETED
- Postoperative Outcomes of PCNL vs RIRS in Obese Patients With Pelvic 1.5:3 cm Renal Stones · COMPLETED
- Influence of DPP-4 on Inflammatory Parameters in Diabetics: Gender Aspects · UNKNOWN
ChEMBL: LAT-8881 · max phase 2.0
What brands say it does
AOD-9604 is the C-terminal fragment of hGH (amino acids 176–191). Trials explored fat reduction without growth effects; results were modest. WADA-prohibited. Sold as a research peptide for body recomposition—evidence is weak.
Where you’ll find it
Weight-loss peptide stacks and research vendors—not approved drugs.
Other names you might see
hGH fragment 176-191 analog
Anti-obesity drug fragment
Compare with similar peptides
Similar peptides
Educational only—not medical advice. We do not sell peptides. Unregulated research chemicals carry serious purity and legal risks.